scholarly journals One-class models for validation of miRNAs and ERBB2 gene interactions based on sequence features for breast cancer scenarios

ICT Express ◽  
2021 ◽  
Author(s):  
Juan Gutiérrez-Cárdenas ◽  
Zenghui Wang
Keyword(s):  
Breast Cancer ◽  
Gene Interactions ◽  
Sequence Features ◽  
Erbb2 Gene ◽  
Class Models

The effect of timing of breast cancer surgery during the menstrual cycle phase on the axillary lymph node, estrogen receptor, progesterone receptor and c-erb B2

2020 ◽  
Author(s):  
Berrin Papila Kundaktepe Specialist ◽  
Sinem Durmus ◽  
Cigdem Papila ◽  
Mehmet Velidedeoglu ◽  
Remise Gelisgen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Menstrual Cycle ◽  
Progesterone Receptor ◽  
Luteal Phase ◽  
Breast Cancer Surgery ◽  
Cycle Phase ◽  
Axillary Lymph ◽  
Menstrual Cycle Phase ◽  
Erbb2 Gene

Abstract Background: Estrogen receptor (ER) and progesterone receptor (PR) positivity and c-erbB2 gene expression levels are important in determining breast cancer (BC) development and aggression. Although the importance of hormonal factors in tumor cell proliferation, migration and differentiation is increasing, it needs more evidence. The effect of BC surgery timing during the menstrual cycle on prognosis remains controversial. In order to clarify this hypothesis, we aimed to determine the importance of adjusting the timing of surgery according to the menstrual cycle by examining the relationship between ER, PR, c-erbB2 gene and the menstrual cycle phase in patients with premenopausal BC.Method: Our study was designed retrospectively. 50 patients with premenopausal BC who were operated were included in the study.Results: Our results showed that the patients in the luteal phase had higher ER positivity, PR positivity and c-erbB2 negativity, and the number of metastatic axillary lymph nodes was lower than the patients in follicular phase. Conclusion: BC surgery during the luteal phase in pre-menopausal women is associated with a better clinical outcome. Although larger-scale studies are needed, our results suggest that better results can be achieved by performing surgery in luteal phase in BC patients during premenopausal period.

scholarly journals Relapsed Classic E-Cadherin (CDH1)–Mutated Invasive Lobular Breast Cancer Shows a High Frequency of HER2 (ERBB2) Gene Mutations

2013 ◽  
Vol 19 (10) ◽  
pp. 2668-2676 ◽  
Author(s):  
Jeffrey S. Ross ◽  
Kai Wang ◽  
Christine E. Sheehan ◽  
Ann B. Boguniewicz ◽  
Geoff Otto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Frequency ◽  
Gene Mutations ◽  
Lobular Breast Cancer ◽  
Erbb2 Gene ◽  
Invasive Lobular Breast Cancer ◽  
E Cadherin

scholarly journals Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1219
Author(s):  
Philip S. Bernard ◽  
Whitney Wooderchak-Donahue ◽  
Mei Wei ◽  
Steven M. Bray ◽  
Kevin C. Wood ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Adverse Events ◽  
Proton Pump ◽  
Gene Interactions ◽  
Potential Utility ◽  
Dose Selection ◽  
The Us ◽  
Inflammatory Drugs ◽  
Us Fda

Patients with breast cancer often receive many drugs to manage the cancer, side effects associated with cancer treatment, and co-morbidities (i.e., polypharmacy). Drug–drug and drug–gene interactions contribute to the risk of adverse events (AEs), which could lead to non-adherence and reduced efficacy. Here we investigated several well-characterized inherited (germline) pharmacogenetic (PGx) targets in 225 patients with breast cancer. All relevant clinical, pharmaceutical, and PGx diplotype data were aggregated into a single unifying informatics platform to enable an exploratory analysis of the cohort and to evaluate pharmacy ordering patterns. Of the drugs recorded, there were 38 for which high levels of evidence for clinical actionability with PGx was available from the US FDA and/or the Clinical Pharmacogenetics Implementation Consortium (CPIC). These data were associated with 10 pharmacogenes: DPYD, CYP2C9, CYP2C19, CYP2D6, CYP3A5, CYP4F2, G6PD, MT-RNR1, SLCO1B1, and VKORC1. All patients were taking at least one of the 38 drugs and had inherited at least one actionable PGx variant that would have informed prescribing decisions if this information had been available pre-emptively. The non-cancer drugs with PGx implications that were common (prescribed to at least one-third of patients) included anti-depressants, anti-infectives, non-steroidal anti-inflammatory drugs, opioids, and proton pump inhibitors. Based on these results, we conclude that pre-emptive PGx testing may benefit patients with breast cancer by informing drug and dose selection to maximize efficacy and minimize AEs.

scholarly journals A second erb-B receptor tyrosine kinase, ERBB4, is differentially expressed in the tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Growth Factor Receptor ◽  
Differentially Expressed ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Trastuzumab Treatment ◽  
Erbb2 Gene ◽  
Epidermal Growth

HER2, the human epidermal growth factor receptor 2, is encoded by the ERBB2 gene (1). Trastuzumab, a monoclonal antibody that targets HER2, is utilized for the treatment of breast cancer (2). We recently reported that trastuzumab treatment paradoxically increases HER2 expression in the primary tumors of patients with breast cancer (3). We report here, using analysis of published microarray data (4, 5), that a second erb-B receptor tyrosine kinase, ERRB4, is also differentially expressed in the tumors of patients with breast cancer treated with trastuzumab. Trastuzumab treatment appears to be associated with the up-regulation of two members of the erb-B receptor tyrosine kinase family in human breast cancer.

scholarly journals Ranking Variable Combinations to Characterize Breast Cancer Subtypes using the IBIF-RF Metric

10.29007/8xwn ◽  
2020 ◽  
Author(s):  
Isis Narvaez-Bandera ◽  
Wandaliz Torres-Garcia
Keyword(s):  
Breast Cancer ◽  
Complex Problem ◽  
Breast Cancer Subtypes ◽  
High Dimensionality ◽  
Gene Interactions ◽  
Computational Results ◽  
Multiple Features ◽  
Cancer Subtypes ◽  
Data Mining Approach ◽  
Definition Of

Gene interactions play a fundamental role in the proneness to cancer. However, detect- ing and ranking these interactions is a complex problem due to the high dimensionality of genomic data. Hence, we aim to find patterns composed of multiple features to molecularly characterize breast cancer subtypes from the integration of different omics datasets using a data mining approach. To retrieve biological understanding from these computational results, we developed IBIF-RF (Importance Between Interactive Features using Random Forest), a new metric capable of assessing and holistically ranking the importance of genomic interactions without any prior knowledge of key feature combinations. A set of 247 top-performing features from transcriptomic, proteomic, methylation, and clinical data were used to investigate interactive patterns to classify breast cancer subtypes us- ing over 1150 samples. IBIF-RF metric allowed the extraction of 154312, 190481, and 463917 combinations of variables for TCGA, GSE20685, and GSE21653 datasets. Single genes, MLPH and FOXA1, were the most frequently identified variables across all datasets followed by some two-gene interactions such as CEP55-FOXA1 and FOXC1-THSD4. More- over, IBIF-RF metric allowed the definition of two sets of genes frequently found together (1: FOXA1, MLPH, and SIDT1, and 2: CEP55, ASPM, CENPL, AURKA, ESPL1, TTK, UBE2T, NCAPG, GMPS, NDC80, MYBL2, KIF18B, and EXO1).

scholarly journals Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant

2021 ◽  
Vol 11 ◽  
Author(s):  
Zhichao Gao ◽  
Junnan Xu ◽  
Yan Wang ◽  
Jie Wu ◽  
Tao Sun
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Advanced Breast Cancer ◽  
Effective Treatment ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Her2 Overexpression ◽  
Erbb2 Gene ◽  
Heavily Pretreated

The prognosis for female patients with locally advanced breast cancer (LABC) has improved with the emergence of novel drugs, especially for those who have HER2 overexpression or ERBB-2 amplification. Trastuzumab-based regimen has been the paradigm in guidelines as first-line therapy, whereas many patients got progressive disease after several cycles of treatment or rapidly progress because of primary resistance. Point mutations of ERBB2 gene occur in both HER2-amplication and non-amplification patients, with a 2% ratio in HER2 non-amplification cohort and 1.48% in HER2 amplication population. The acquired mutation ratio of ERBB2 substantially raised to 16.7%–17.7% in patients prior to trastuzumab treatment. ERBB2 mutation may be a critical reason of resistance and disease progression among the patients treated with anti-HER2 monoclonal trastuzumab or dual anti-HER2 antibodies with trastuzumab and pertuzumab, or tyrosine-kinase inhibitor. ERBB-2 mutation with L755S and V842I indicates resistance to trastuzumab, while that with L755S and K753I indicates resistance to lapatinib; these mutations maybe sensitive to pan-HER tyrosine-kinase inhibitors. A 48-year woman diagnosed with HER2-positive LABC developed trastuzumab resistance after three lines of trastuzumab cross-line treatment with partial response (PR) as the best response. The tissue was performed by next-generation sequencing (NGS), and the results discovered L755S in ERBB2 gene. Then, she received effective treatment with pyrotinib plus capecitabine and underwent mastectomy after six cycles of combined treatment with PR. Subsequently, breast mastectomy was performed, and she took pyrotinib plus capecitabine for 1 year and pyrotinib monotherapy for another 1 year as adjuvant therapy and achieved a long-term clinical benefit. In conclusion, pyrotinib is a potential neoadjuvant agent for patients who are heavily pretreated and harbor both ERBB2 amplification and ERBB2 mutant in locally advanced breast cancer.

Sign in / Sign up

Export Citation Format

Share Document